ONCOLOGY CONTRACT 
MANUFACTURING

At Baxter’s manufacturing facility dedicated to oncology products in Halle/Westfalen, Germany, all of your parenteral needs are handled at one location, enabling processing solutions to fit your compound.

Your oncology products can make a difference in patients’ lives. 

Our oncology manufacturing expertise can help you make that difference.

Global Experience

More than 60 years of oncology experience manufacturing products sold worldwide including North America, South America, Europe and Asia.

Broad Expertise

Dedicated clinical through commercial production with integrated technologies and services. Specialized areas of focus include cytotoxics, highly potent compounds, biologics, lyophilized products, and antibody-drug conjugates (ADCs).

Maximizing Manufacturing Value

Baxter’s Halle facility offers state-of-the-art cGMP manufacturing, uniquely designed to deliver high-quality products with optimum efficiency and speed to market.

To discuss sterile contract manufacturing services for injectable molecules, please contact us at: 
United States: 1-800-4-BAXTER 
International: 1-224-948-4770

Go to article: Home | Getting the skinny on generics labellingGo to article: In this issueGo to article: ContentsGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: The Solubility companyGo to article: The Solubility Company Insight Go to article: CommentGo to article: Market access of orphan designated therapies at riskGo to article: Lodo Therapeutics’ AI-driven natural drug discovery platformGo to article: Concert Pharmaceuticals discontinues schizophrenia drug after trial failureGo to article: Medical cannabis in Europe: a compelling opportunityGo to article: Exploring the pharma deals outlook in 2021Go to article: In DepthGo to article: Skinny labelling of generics: the beginning of the end for this practice?Go to article: Charting the choppy history of ‘magic bullet’ antibody-drug conjugates Go to article: How a sleeping drug awakened a patient with akinetic mutismGo to article: Breast cancer research: addressing the pre-menopausal problemGo to article: Beyond the lung: treating the GI symptoms of Covid-19Go to article: Immortal cells and informed consent: the legacy of Henrietta LacksGo to article: How radiopharmaceuticals are helping fight cancer with Fusion Go to article: Competition heats up as new HIV prevention drug shows promise Go to article: BaxterGo to article: ACG WorldwideGo to article: In DataGo to article: Inside the dealGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue